Search Results
May 26, 2026, 06:00 ET HaystackID Advances AI-Enabled Privacy, Security and Legal Discovery Across European Market
intelligence. The European rollout brings these capabilities to a market navigating some of the world's most demanding regulatory frameworks, from GDPR and the EU AI Act to NIS2 and DORA."Legal and regulatory obligations across Europe have become increasingly complex, and the rapid adoption of AI is compounding
More news about: HaystackID
May 26, 2026, 05:32 ET Soft Tissue Sarcoma with Lung Metastases Market Set to Expand Across the 7MM During the Forecast Period (2026-2036) with Advancing Targeted and Cellular Therapies | DelveInsight
market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
More news about: DelveInsight Business Research, LLP
May 26, 2026, 04:39 ET 15 năm theo đuổi đổi mới sáng tạo đỉnh cao: Từ pin sạc dự phòng đến chip AI THUS™ độc quyền
multimedia:https://www.prnewswire.com/vn/news-releases/u0031u0035u002Du006Eu0103u006Du002Du0074u0068u0065u006Fu002Du0111u0075u1ED5u0069u002Du0111u1ED5u0069u002Du006Du1EDBu0069u002Du0073u0061u006E-302781622.htmlSOURCE
More news about: Anker Innovations
May 26, 2026, 04:17 ET Huawei tổ chức Hội nghị các nhà tiên phong C&I toàn cầu lần thứ 3, cùng kiến tạo tương lai xanh cho nhiều ngành
multimedia:https://www.prnewswire.com/vn/news-releases/u0068u0075u0061u0077u0065u0069u002Du0074u1ED5u002Du0063u0068u1EE9u0063u002Du0068u1ED9u0069u002Du006Eu0067u0068u1ECBu002Du0063u0061u0063u002D-302781606.htmlSOURCE
More news about: Huawei Digital Power
May 26, 2026, 00:24 ET Hikvision ứng dụng AI vào công nghệ nén video với Guanlan Encoding, giúp giảm tới 50% chi phí lưu trữ
multimedia:https://www.prnewswire.com/vn/news-releases/u0068u0069u006Bu0076u0069u0073u0069u006Fu006Eu002Du1EE9u006Eu0067u002Du0064u1EE5u006Eu0067u002Du0061u0069u002Du0076u0061u006Fu002Du0063u006F-302781493.htmlSOURCE
More news about: Hikvision
May 25, 2026, 22:53 ET Hansa Biopharma Announces Late-Breaking Abstract from ConfIdeS Phase 3 Trial Selected for Oral Presentation at ATC 2026
options.8The efficacy and safety of imlifidase as a pre-transplant treatment to reduce donor-specific IgG antibodies was studied in four phase 2 single-arm, studies in EU and US as well as a randomized, controlled Phase 3 study in US.5,7,10-11 Hansa is collecting further clinical evidence and will
More news about: Hansa Biopharma AB
May 25, 2026, 22:52 ET Hansa Biopharma Announces Late-Breaking Abstract from ConfIdeS Phase 3 Trial Selected for Oral Presentation at ATC 2026
options.8The efficacy and safety of imlifidase as a pre-transplant treatment to reduce donor-specific IgG antibodies was studied in four phase 2 single-arm, studies in EU and US as well as a randomized, controlled Phase 3 study in US.5,7,10-11 Hansa is collecting further clinical evidence and will
More news about: Hansa Biopharma AB
May 25, 2026, 21:00 ET 1291 Group Mua Lại IPG, Củng Cố Năng Lực Bảo Vệ Tài Sản Toàn Cầu Trên Khắp Châu Mỹ
content:https://www.prnewswire.com/vn/news-releases/u0031u0032u0039u0031u002Du0067u0072u006Fu0075u0070u002Du006Du0075u0061u002Du006Cu1EA1u0069u002Du0069u0070u0067u002Cu002Du0063u1EE7u006Eu0067-302779000.htmlSOURCE
More news about: 1291 Group
May 25, 2026, 17:31 ET Pulmonary Arterial Hypertension Market Outlook Shows Strong Upward Trend at a CAGR of 6.7% During the Study Period (2022-2036) Supported by New Clinical Developments | DelveInsight
market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
More news about: DelveInsight Business Research, LLP
May 25, 2026, 14:28 ET AFX ra mắt Chương trình tích điểm trên Mainnet nhằm khen thưởng nhà giao dịch, nhà cung cấp thanh khoản và cộng đồng tham gia thực chất
multimedia:https://www.prnewswire.com/vn/news-releases/u0061u0066u0078u002Du0072u0061u002Du006Du1EAFu0074u002Du0063u0068u01B0u01A1u006Eu0067u002Du0074u0072u0069u006Eu0068u002Du0074u0069u0063u0068-302781278.htmlSOURCE
More news about: AFX
May 25, 2026, 14:18 ET Xinhua Silk Road: 역사적인 홍차 브랜드, 중국 남동부 푸젠 농촌 번영 견인
multimedia:https://www.prnewswire.com/kr/news-releases/u0078u0069u006Eu0068u0075u0061u002Du0073u0069u006Cu006Bu002Du0072u006Fu0061u0064u003Au002DuC5EDuC0ACuC801uC778u002DuD64DuCC28u002DuBE0CuB79C-302781270.htmlSOURCE
More news about: Xinhua Silk Road
May 25, 2026, 13:33 ET Shuying Technology tỏa sáng tại ILDEX Vietnam: Ký kết thỏa thuận hợp tác chiến lược nhằm thúc đẩy chăn nuôi lợn thông minh trên toàn ASEAN
multimedia:https://www.prnewswire.com/vn/news-releases/u0073u0068u0075u0079u0069u006Eu0067u002Du0074u0065u0063u0068u006Eu006Fu006Cu006Fu0067u0079u002Du0074u1ECFu0061u002Du0073u0061u006Eu0067u002D-302781247.htmlSOURCE
More news about: Shuying Technology
May 25, 2026, 11:45 ET Universal Music Group N.V. Reports Weekly Transactions under its €500 Million Share Buyback Program
press release is issued in connection with the disclosure and reporting obligations set out in Regulation (EU) No 596/2014 (the Market Abuse Regulation) and Commission Delegated Regulation (EU) 2016/1052 (each as amended).About Universal Music GroupAt Universal Music Group, we exist
More news about: Universal Music Group N.V.
May 25, 2026, 11:45 ET Universal Music Group N.V. Reports Weekly Transactions under its €500 Million Share Buyback Program
press release is issued in connection with the disclosure and reporting obligations set out in Regulation (EU) No 596/2014 (the Market Abuse Regulation) and Commission Delegated Regulation (EU) 2016/1052 (each as amended).About Universal Music GroupAt Universal Music Group, we exist
More news about: Universal Music Group N.V.
May 25, 2026, 11:31 ET MoonPay Wins 2026 Chainalysis Innovation Award for Compliance
BitLicense, a New York Limited Purpose Trust Charter, and money transmitter licenses across the United States, as well as MiCA authorization in the EU. MoonPay is how the world moves value.For media enquiries, contact:[email protected]
More news about: MoonPay
May 25, 2026, 10:30 ET GoodWe met en avant la simplicité et la rapidité d'installation de la série ESA lors de son troisième événement de lancement européen à Francfort
réseaux et au fonctionnement en îlotage complet.Un défi d'installation qui démontre la facilité d'utilisationLes installateurs ont eu l'occasion de s'impliquer activement dans le stockage d'énergie de l'ESA en participant à une course d'installation. Les tâches de configuration du système
More news about: GoodWe
May 25, 2026, 10:23 ET AHA Connection Day: Socialite Hospitality Night kết nối cộng đồng ngành khách sạn và du lịch Úc - Việt tại Nha Trang
multimedia:https://www.prnewswire.com/vn/news-releases/u0061u0068u0061u002Du0063u006Fu006Eu006Eu0065u0063u0074u0069u006Fu006Eu002Du0064u0061u0079u003Au002Du0073u006Fu0063u0069u0061u006Cu0069u0074-302781173.htmlSOURCE
More news about: AHA Vietnam
May 25, 2026, 08:17 ET Youcom aposta na cocriação com Sarina Gomes para transformar influência em construção de marca
sobre seguir tendência, é sobre construir narrativa e identidade. Essa collab nasce justamente desse lugar, de transformar referência em expressão real. Eu quis trazer elementos que fazem parte da minha história, da minha estética e da minha cultura, mas traduzidos de uma forma atual, que conversa com o
More news about: Youcom
May 25, 2026, 08:13 ET Menarini Group gibt neue Daten auf der Jahrestagung 2026 der American Society of Clinical Oncology (ASCO) bekannt
Phase-3-Studie SENTRY mit Selinexor bei JAKi-naiven Patienten mit Myelofibrose (MF) halten. Selinexor wird in den USA von Karyopharm Therapeutics und in der EU von Stemline vermarktet.„Die umfangreichen Onkologiedaten, die präsentiert werden und sowohl solide Tumore als auch hämatologische Malignome umfassen,
More news about: Menarini Industrie Farmaceutiche Riunite
May 25, 2026, 08:06 ET Menarini Group annonce de nouvelles données lors de la réunion annuelle 2026 de l'American Society of Clinical Oncology (ASCO)
exposé oral de dernière minute sur l'essai de phase 3 SENTRY portant sur le selinexor chez des patients atteints de myélofibrose (MF) n'ayant jamais eu recours à la JAKi. Selinexor est commercialisé aux États-Unis par Karyopharm Therapeutics et dans l'Union européenne par Stemline.«Les nombreuses
More news about: Menarini Industrie Farmaceutiche Riunite
May 25, 2026, 07:53 ET Pierre Fabre Laboratories erhält positives Gutachten des CHMP für BRAFTOVI® (Encorafenib) in Kombination mit Cetuximab und FOLFOX (Fluorouracil, Leucovorin und Oxaliplatin) zur Erstlinienbehandlung erwachsener Patienten mit BRAFV600E-mutiertem metastasierendem kolorektalen Karzinom (mCRC)
BRAFV600E-mutiertem metastasierendem Kolorektalkarzinom (mCRC). Die positive Stellungnahme wird der Europäischen Kommission (EK) vorgelegt, und eine Entscheidung über die EU-Zulassung wird im Laufe dieses Jahres erwartet.
More news about: Pierre Fabre Laboratories
May 25, 2026, 06:44 ET Menarini Group Announces New Data at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
3 SENTRY trial of selinexor in JAKi naïve patients with myelofibrosis (MF). Selinexor is marketed in the U.S. by Karyopharm Therapeutics, and in the EU by Stemline."The extensive oncology data that will be presented, encompassing both solid tumors and hematologic malignancies, highlights our dedication
More news about: Menarini Industrie Farmaceutiche Riunite
May 25, 2026, 06:22 ET Les Laboratoires Pierre Fabre ont reçu un avis positif du CHMP pour BRAFTOVI® (encorafenib) en association avec le cetuximab et FOLFOX (fluorouracile, leucovorine et oxaliplatine) comme traitement de première ligne chez les patients adultes atteints d'un cancer colorectal métastatique (CCRm) avec mutation BRAFV600E
BRAFTOVI® en association avec le cetuximab et mFOLFOX6 chez des patients atteints d'un CCRm avec mutation BRAFV600E n'ayant pas eu de traitement préalable pour la maladie métastatiqueContact: [email protected] PDF:
More news about: Pierre Fabre Laboratories
May 25, 2026, 06:11 ET Pierre Fabre Laboratories receives CHMP positive opinion for BRAFTOVI® (encorafenib) in combination with cetuximab and FOLFOX (fluorouracil, leucovorin, and oxaliplatin) for the first-line treatment of adult patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC)
BRAFV600E-mutant metastatic colorectal cancer (mCRC). The positive opinion will be submitted to the European Commission (EC) with a decision on EU marketing authorisation expected later this year.
More news about: Pierre Fabre Laboratories
May 25, 2026, 03:37 ET BioArctic's partner Eisai presents sales simulation of potential future sales of Leqembi® at its Investor Relations Day
https://www.eisai.com/ir/library/presentations/index.htmlThis is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact person below, on May 25, 2026,
More news about: BioArctic